Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.

The aims of this report are firstly to raise awareness among kineticists and pharmacologists as to why pharmacokinetic-pharmacodynamic (PKPD) integration is essential for target validation (TV), optimizing development of lead compounds (lead generation [LG] and lead optimization [LO]) and scaling these to human. A related aim is to demonstrate strategic examples of PKPD collaborations that have improved the planning, execution and evaluation of experiments in primary and safety pharmacology. Examples include design of TV studies, design and data 'pruning' of PKPD studies in LO, analysis of data with marginal and substantial temporal (time) differences between exposure and response, design of safety pharmacology studies, assessment of safety margin and assessment of uncertainties in predictions of first dose in human.

[1]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[2]  F. Quimby,et al.  The Clinical chemistry of laboratory animals , 1989 .

[3]  T. Barrett,et al.  Functional pharmacology: the drug discovery bottleneck? , 2004 .

[4]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[5]  V. Alabaster,et al.  The fall and rise of in vivo pharmacology. , 2002, Trends in pharmacological sciences.

[6]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[7]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[8]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[9]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[10]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[11]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[12]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  V F Smolen,et al.  Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administrations of a mydriatic drug. , 1971, Journal of pharmaceutical sciences.

[14]  M. Tabo,et al.  Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization. , 2007, Journal of pharmacological and toxicological methods.

[15]  W. H. Barr,et al.  Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1993, Springer US.

[16]  W. Jusko,et al.  Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles , 2000, Biopharmaceutics & drug disposition.

[17]  G Levy,et al.  Predicting Effective Drug Concentrations for Individual Patients , 1998, Clinical pharmacokinetics.

[18]  Gerhard Levy,et al.  The Case for Preclinical Pharmacodynamics , 1993 .

[19]  G Levy,et al.  Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.

[20]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.